Terbium-161 NCA

Terbium-161 is redefining targeted radiotherapy. With its unique emission of both beta particles and conversion/Auger electrons, Tb-161 delivers potent, localized radiation, ideal for treating small tumors and micrometastases with high precision and minimal damage to surrounding healthy tissue.

Why Terbium-161?

Terbium-161 is a next-generation therapeutic radionuclide that combines the proven benefits of lutetium-177 with an added advantage:

• High-energy Auger electrons for enhanced tumor cell kill
• Comparable chemistry to Lu-177 for easy integration into existing radiopharmaceutical platforms
• Ideal for small tumors and micrometastases
• NCA Grade: No Carrier Added for high specific activity and purity
• GMP Production: Pharmaceutical-grade reliability, ready for clinical use

Clinical Potential

• Designed for targeted radionuclide therapy (TRT)
• Especially effective for neuroendocrine tumors, prostate cancer, and beyond
• Compatible with DOTA-based ligands (e.g., DOTATATE, PSMA)